- Home
- NBP vs FHTX Comparison
NBP vs FHTX Comparison
Compare NBP & FHTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | NBP | FHTX |
|---|---|---|
| Founded | 2014 | 2015 |
| Country | United States | United States |
| Employees | N/A | 106 |
| Industry | Biotechnology: Pharmaceutical Preparations | Medicinal Chemicals and Botanical Products |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 149.2M | 111.1M |
| IPO Year | 2019 | 2020 |
Fundamental Metrics
Financial Performance| Metric | NBP | FHTX |
|---|---|---|
| Price | $1.43 | $2.01 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 2 | 10 |
| Target Price | ★ $9.00 | $4.17 |
| AVG Volume (30 Days) | 672.5K | ★ 1.2M |
| Earning Date | 08-20-2026 | 11-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 25.32 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $30,909,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $15.98 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 36.75 |
| 52 Week Low | $1.26 | $1.79 |
| 52 Week High | $5.19 | $7.61 |
Technical Indicators
Market Signals| Indicator | NBP | FHTX |
|---|---|---|
| Relative Strength Index (RSI) | 33.75 | 17.24 |
| Support Level | N/A | $1.79 |
| Resistance Level | $1.44 | $5.85 |
| Average True Range (ATR) | 0.05 | 0.23 |
| MACD | 0.00 | 0.03 |
| Stochastic Oscillator | 25.00 | 4.14 |
Price Performance
Historical ComparisonAbout NBP NovaBridge Biosciences American Depositary Shares
NovaBridge Biosciences operates as a biotechnology platform, combining business development and clinical research to identify and advance pharmaceutical assets. Its inventive immuno-oncology pipeline consists of three clinical stage programs, givastomig; uliledlimab; and ragistomig. Its core product, givastomig, is a potential in-class CLDN18.2 bispecific antibody for the treatment of gastric cancer and other CLDN18.2-positive gastrointestinal malignancies.
About FHTX Foghorn Therapeutics Inc.
Foghorn Therapeutics Inc is a clinical stage, precision therapeutics biotechnology company focused on pioneering a new class of medicines that treat serious diseases by correcting abnormal gene expression through selectively targeting the chromatin regulatory system. Its proprietary platform is designed to provide an integrated, mechanistic understanding of interactions within the chromatin regulatory system, supporting the identification and validation of potential therapeutic targets. The company's flagship program is FHD-909.